Neurosarcoidosis: guidance for the general neurologist

• Autor(a) principal: Dutra,Lívia Almeida
• Data de Publicação: 2012
• Outros Autores: Braga-Neto,Pedro, Oliveira,Ricardo Araújo, Pedroso,José Luiz, Abrahão,Agessandro, Barsottini,Orlando Graziani Povoas
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2012000400014
• topic: sarcoidosis; neurosarcoidosis; methotrexate; azathioprine; cyclophosphamide; infliximab

Neurosarcoidosis (NS) more commonly occurs in the setting of systemic disease. The diagnosis is based on a clinical history suggestive of NS, presence of noncaseating granulomas, and supportive evidence of sarcoid pathology, laboratory, and imaging studies. NS could involve any part of the nervous system and often demands high doses of steroids for symptom control. It presents low response to isolated steroids administration and frequently requires immunosuppressive agents. In NS, lymphocytes are polarized toward an excessive Th1 response, leading to overproduction of TNF-alpha and INF-gama, as well as lL-2 and IL-15. Infliximab, a chimeric monoclonal antibody that neutralizes the biological activity of TNF-alpha, is a new option in the NS treatment. We revised pathophysiology, clinical manifestations, diagnostic work up, and treatment of NS as guidance for the general neurologist.